Skip to main content
Top
Published in: Forensic Science, Medicine and Pathology 2/2019

01-06-2019 | Suicide | Case Report

Fatal overdose with a combination of SNRIs venlafaxine and duloxetine

Authors: Armin Alibegović, Stojan Kariž, Metka Volavšek

Published in: Forensic Science, Medicine and Pathology | Issue 2/2019

Login to get access

Abstract

Drugs for the treatment of depressive disorders, including SNRIs (serotonin noradrenaline reuptake inhibitors) venlafaxine and duloxetine, are widely prescribed as they have a high therapeutic to toxicity ratio. In rare cases, adverse effects may be severe, usually due to iatrogenic, accidental or intentional self-overdose that cause the excessive accumulation of serotonin and noradrenaline in synaptic clefts. Lethal intoxication with a combination of venlafaxine and duloxetine (postmortem blood concentrations 24 mg/L and 0.97 mg/L, respectively) without co-ingested substances, comorbidities or injuries that could have an unknown contribution to a fatal outcome is presented for the first time in the following case report, with a comprehensive clinical history, and complete results of the performed analyses. The cause of death was a serotonin syndrome that progressed to death in approximately six hours and 15 min after the suicidal ingestion of venlafaxine and duloxetine. Despite the high therapeutic to toxicity ratio SNRIs, which are reserved for patients with severe forms of depressive disorders and a higher suicidal tendency, they should be cautiously prescribed and handed over in smaller packages to make them easier to follow, and thus avoid accumulation within the patient’s reach.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003;5:153–7.CrossRefPubMedPubMedCentral Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003;5:153–7.CrossRefPubMedPubMedCentral
2.
go back to reference Moffat AC, Osselton MD, Widdop B, editors. Clarke’s analysis of drugs and poisons. 4th ed. London: Pharmaceutical Press; 2011. Moffat AC, Osselton MD, Widdop B, editors. Clarke’s analysis of drugs and poisons. 4th ed. London: Pharmaceutical Press; 2011.
3.
go back to reference Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013;3:151–61.CrossRefPubMedPubMedCentral Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013;3:151–61.CrossRefPubMedPubMedCentral
4.
go back to reference Buccelli C, Vacchiano G, Niola M, Graziano V, Basilicata P, Silvestre A, et al. On an engaged case of cardiac arrhythmia following duloxetine intoxication. Rom J Leg Med. 2017;25:60–4.CrossRef Buccelli C, Vacchiano G, Niola M, Graziano V, Basilicata P, Silvestre A, et al. On an engaged case of cardiac arrhythmia following duloxetine intoxication. Rom J Leg Med. 2017;25:60–4.CrossRef
5.
go back to reference Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, et al., editors. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): AHRQ Comparative Effectiveness Reviews; 2011. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, et al., editors. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): AHRQ Comparative Effectiveness Reviews; 2011.
6.
go back to reference Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–42.CrossRefPubMed Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–42.CrossRefPubMed
7.
go back to reference Gundogmus I, Ispir M, Bakkal O, Karagoz A, Maden O, Algul A, et al. Venlafaxine-induced prostatism: a case report. Psych Clin Psychopharmacol. 2017;27:197–8.CrossRef Gundogmus I, Ispir M, Bakkal O, Karagoz A, Maden O, Algul A, et al. Venlafaxine-induced prostatism: a case report. Psych Clin Psychopharmacol. 2017;27:197–8.CrossRef
8.
go back to reference Pilgrim JL, Gerostamoulos D, Drummer OH. The prevalence of duloxetine in medico-legal death investigation in Victoria, Australia (2009-2012). Forensic Sci Int. 2014;234:165–73.CrossRefPubMed Pilgrim JL, Gerostamoulos D, Drummer OH. The prevalence of duloxetine in medico-legal death investigation in Victoria, Australia (2009-2012). Forensic Sci Int. 2014;234:165–73.CrossRefPubMed
9.
go back to reference Menchetti M, Gozzi BF, Saracino MA, Mercolini L, Petio C, Raggi MA. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry. 2009;10:385–9.CrossRefPubMed Menchetti M, Gozzi BF, Saracino MA, Mercolini L, Petio C, Raggi MA. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry. 2009;10:385–9.CrossRefPubMed
10.
go back to reference Boyer E, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.CrossRef Boyer E, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.CrossRef
11.
go back to reference Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23:15–26.CrossRefPubMed Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23:15–26.CrossRefPubMed
12.
go back to reference Ellahi R. Serotonin syndrome: a spectrum of toxicity. BJPsych Advances. 2015;21:324–32.CrossRef Ellahi R. Serotonin syndrome: a spectrum of toxicity. BJPsych Advances. 2015;21:324–32.CrossRef
13.
go back to reference Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.CrossRef Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.CrossRef
14.
go back to reference Launiainen T, Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test Anal. 2014;6:308–16.CrossRefPubMed Launiainen T, Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test Anal. 2014;6:308–16.CrossRefPubMed
15.
go back to reference Anderson D, Reed S, Lintemoot J, Kegler S, DeQuintana S, Sandberg M, et al. A first look at duloxetine (Cymbalta) in a postmortem laboratory. J Anal Toxicol. 2006;30:576–80.CrossRefPubMed Anderson D, Reed S, Lintemoot J, Kegler S, DeQuintana S, Sandberg M, et al. A first look at duloxetine (Cymbalta) in a postmortem laboratory. J Anal Toxicol. 2006;30:576–80.CrossRefPubMed
16.
go back to reference Paulzen M, Hiemke C, Grunder G. Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. Int J Neuropsychopharmacol. 2009;12:1431–2.CrossRefPubMed Paulzen M, Hiemke C, Grunder G. Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. Int J Neuropsychopharmacol. 2009;12:1431–2.CrossRefPubMed
17.
go back to reference Höjer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila). 2008;46:336–7.CrossRef Höjer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila). 2008;46:336–7.CrossRef
18.
go back to reference Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23:Suppl 1:43–51. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23:Suppl 1:43–51.
Metadata
Title
Fatal overdose with a combination of SNRIs venlafaxine and duloxetine
Authors
Armin Alibegović
Stojan Kariž
Metka Volavšek
Publication date
01-06-2019
Publisher
Springer US
Published in
Forensic Science, Medicine and Pathology / Issue 2/2019
Print ISSN: 1547-769X
Electronic ISSN: 1556-2891
DOI
https://doi.org/10.1007/s12024-019-00097-3

Other articles of this Issue 2/2019

Forensic Science, Medicine and Pathology 2/2019 Go to the issue